GlassScriptPhysician profile
Rimas V Lukas
NPI 1396954269
$249,106.83
in general payments reported to CMS, 2019-2025
16 companies · $92K in 2025
The $92K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,015 · 2020: $21K · 2021: $14K · 2022: $16K · 2023: $49K · 2024: $53K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $62K · Consulting Fee: $48K · Honoraria: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $18K · Grant: $6,282 · Food and Beverage: $5,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $62,475.00 |
| Consulting Fee | $47,932.25 |
| Honoraria | $33,275.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,947.50 |
| Travel and Lodging | $17,783.37 |
| Grant | $6,282.44 |
| Food and Beverage | $5,194.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $105,855.29 | 2019-2025 | Optune, Optune Gio |
| Servier Pharmaceuticals LLC | $74,723.17 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $40,157.28 | 2021-2025 | Welireg |
| Novartis Pharmaceuticals Corporation | $9,201.19 | 2023-2024 | |
| Gt Medical Technologies, INC | $4,021.98 | 2023-2025 | Gammatile, Gammatile |
| Biogen, INC. | $3,050.00 | 2019-2021 | |
| Telix Pharmaceuticals | $2,620.74 | 2024-2025 | Illuccix |
| Catalyst Pharmaceuticals, INC. | $2,367.48 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,712.50 | 2023 | Imfinzi |
| Abbvie INC. | $1,487.50 | 2019 | |
| Eisai INC. | $1,440.00 | 2019 | |
| Monteris Medical Corporation | $982.91 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $966.30 | 2022-2023 | |
| Celularity INC. | $288.77 | 2021-2022 | |
| Boston Scientific Corporation | $123.74 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $107.98 | 2024 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rimas Lukas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.